Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model

EAST SETAUKET, NY -- (Marketwired) -- 04/17/17 -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) presented a late-breaking abstract entitled "Protein phosphatase 2A inhibition with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated antitumor activity when combined with PD-1 blockade in a preclinical model" as a poster (abstract number LB-193) at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, DC on April 4th. This research was done in collaboration with scientists at the National Institute of Neurological Disorders and Stroke (NINDS), NIH.

Dr. John S. Kovach, CEO of Lixte, said, "The study shows that in an animal model Lixte's lead clinical compound, LB-100 has synergistic potential in conjunction with immune checkpoint blockade supporting investigation of its ability to enhance immunotherapy in the clinic. LB-100, a novel, first-in-class, small molecule inhibitor of protein phosphatase 2A (PP2A), recently completed a Phase 1 trial in patients with advanced cancer (Chung 2016). In that trial, LB-100, was well tolerated at doses associated with stabilization of progressive solid tumors in 10 of 21 patients with receiving 2 or more courses of treatment. One patient with previously refractory pancreatic cancer had a partial regression for 11 months."

Dr. Kovach continued, "Based on a number of published preclinical studies, we had expected that LB-100 will be therapeutically useful primarily as a potentiator of cytotoxic anti-cancer drugs and x-ray. The present study, however, raises the possibility that, in addition, LB-100 may have a role in enhancing the efficacy of so-called 'immune checkpoint blockers' -- agents that allow patients' own immune system to attack their own cancers."

About Lixte Biotechnology Holdings, Inc.
Lixte is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases.

Forward-Looking Statements
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml.

Additional information on the Company is available at www.lixte.com.

Contact info:
eforman@lixte.com
(631) 830-7092

Source: Lixte Biotechnology Holdings, Inc.

Released April 17, 2017